So Many Studies, Too Few Subjects: Establishing Functional Relevance of Genetic Polymorphisms on Pharmacokinetics

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of clinical pharmacology

• Publication date

  2006-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1177/0091270005283463PMID 16490801
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

  2005cited by this paper
• Clinical Consequences of Cytochrome P450 2C9 Polymorphisms

  2005cited by this paper
• In vitro ADME phenotyping in drug discovery: current challenges and future solutions.

  2005cited by this paper
• FUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA

  2005cited by this paper
• An association study of 43 SNPs in 16 candidate genes with atorvastatin response

  2005cited by this paper
• Drug-drug interactions for UGT substrates: a pharmacokinetic explanation for typically observed low exposure (AUC i /AUC) ratios

  2004cited by this paper
• CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers

  2004cited by this paper
• Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects

  2004cited by this paper
• Novel CYP2C9 genetic variants in asian subjects and their influence on maintenance warfarin dose

  2004cited by this paper
• Effect of the novel anxiolytic drug deramciclane on cytochrome P450 2D6 activity as measured by desipramine pharmacokinetics

  2004cited by this paper
• Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states

  2004cited by this paper
• The regulation of pharmacogenomics-based drugs and policy making.

  2004cited by this paper
• Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.

  2004cited by this paper
• CYP3A5 Genotype and Midazolam Clearance in Australian Patients Receiving Chemotherapy

  2004cited by this paper
• CYP3A5 and MDR1 Genetic Polymorphisms and Cyclosporine Pharmacokinetics After Renal Transplantation

  2004cited by this paper
• The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients.

  2004cited by this paper
• Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics.

  2004cited by this paper
• CYP3A5 Genotype has a Dose‐dependent Effect on ABT‐773 Plasma Levels

  2004cited by this paper
• Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients

  2004cited by this paper
• Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2

  2004cited by this paper
• ABCG2 – a transporter for all seasons

  2004cited by this paper
• The MDR1 (ABCB1) Gene Polymorphism and its Clinical Implications

  2004cited by this paper
• High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).

  2004cited by this paper
• The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.

  2004cited by this paper
• DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

  2004cited by this paper
• Clinical aspects of the MDR1 (ABCB1) gene polymorphism.

  2004cited by this paper
• Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans

  2004cited by this paper
• Truncated Area Under the Curve as a Measure of Relative Extent of Bioavailability: Evaluation Using Experimental Data and Monte Carlo Simulations

  2004cited by this paper
• Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials

  2004cited by this paper
• Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.

  2003cited by this paper
• Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.

  2003cited by this paper
• The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

  2003cited by this paper
• Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics

  2003cited by this paper
• Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism.

  2003cited by this paper
• Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms

  2003cited by this paper
• Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12

  2003cited by this paper
• Reaction phenotyping in drug discovery: moving forward with confidence?

  2003cited by this paper
• C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

  2002cited by this paper
• A Naturally Occurring Mutation in the SLC21A6Gene Causing Impaired Membrane Localization of the Hepatocyte Uptake Transporter*

  2002cited by this paper
• Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.

  2002cited by this paper
• Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis.

  2002cited by this paper
• Polymorphisms in OATP-C

  2001cited by this paper
• Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.

  2000cited by this paper
• Assessment of the Quality and Quantity of Drug‐Drug Interaction Studies in Recent NDA Submissions: Study Design and Data Analysis Issues

  1999cited by this paper
• Truncated Area Under the Curve as a Measure of Relative Extent of Bioavailability: Evaluation Using Experimental Data and Monte Carlo Simulations

  1998cited by this paper
• Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine

  1993cited by this paper
• A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability

  1987cited by this paper

• Pharmacogenetic influence on bupropion bioactivation and clinical outcomes in major depressive disorder.

  2026cites this paper
• Pharmacokinetic Monitoring of Antiepileptic Drugs 327 trabajo de farmacocinética y farmacogenética de la Sociedad Española de Farmacia Hospitalaria

  2017cites this paper
• Evaluating Factors Associated with Tenofovir-Related Kidney Injury in HIV-Infected Women

  2016cites this paper
• Prediction of In Vivo Clearance and Associated Variability of CYP2C19 Substrates by Genotypes in Populations Utilizing a Pharmacogenetics-Based Mechanistic Model

  2015cites this paper
• Common clinical conditions – age, low BMI, ritonavir use, mild renal impairment – affect tenofovir pharmacokinetics in a large cohort of HIV-infected women

  2014cites this paper
• Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk

  2014cites this paper
• Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure

  2013cites this paper
• Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus.

  2012cites this paper
• harmacokinetic Monitoring of Antiepileptic Drugs

  2012cites this paper
• Chapter 11: Challenges in and Principles for Conducting Systematic Reviews of Genetic Tests used as Predictive Indicators

  2012cites this paper
• Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics

  2012cites this paper
• Methods Guide for Medical Test Reviews

  2012cites this paper
• Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese Patients

  2011cites this paper
• Genetic polymorphisms in placental transporters: implications for fetal drug exposure to oral antidiabetic agents

  2011cites this paper
• Pharmacokinetic Monitoring of Antiepileptic Drugs

  2011cites this paper
• Probe Cocktail Studies

  2011cites this paper
• Pharmacokinetic monitoring of antiepileptic drugs.

  2011cites this paper
• A Quantitative Framework and Strategies for Management and Evaluation of Metabolic Drug-Drug Interactions in Oncology Drug Development

  2010cites this paper
• Pharmacogenetic influences on mycophenolate therapy.

  2010cites this paper
• Nonnucleoside Reverse Transcriptase Inhibitor Pharmacokinetics in a Large Unselected Cohort of HIV-Infected Women

  2009cites this paper
• Trends in Pharmacogenomic Epidemiology: 2001–2007

  2009cites this paper
• Pharmacokinetic Drug Interaction Studies Must Consider Pharmacological Heterogeneity, Use of Repeated Dosing, and Translation Into a Message Understandable to Practicing Clinicians

  2009cites this paper
• Therapeutic monitoring of mycophenolate in transplantation: is it justified?

  2009cites this paper
• [Pharmacogenetics in Parkinson's disease treatment].

  2008cites this paper
• Pharmacokinetics/Genotype Associations for Major Cytochrome P450 Enzymes in Native and First‐ and Third‐generation Japanese Populations: Comparison With Korean, Chinese, and Caucasian Populations

  2008cites this paper
• Pharma, clinicians and the lab come together over personalized medicine.

  2007cites this paper
• The Role of Pharmacogenetics in the Metabolism of Antiepileptic Drugs

  2007cites this paper
• Incorporating In Vitro Information on Drug Metabolism Into Clinical Trial Simulations to Assess the Effect of CYP2D6 Polymorphism on Pharmacokinetics and Pharmacodynamics: Dextromethorphan as a Model Application

  2007cites this paper
• Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes.

  2007cites this paper
• Genetic association analysis of polymorphisms in four cytochrome P450 genes, the MDR1 gene and treatment-outcome in Xhosa schizophrenia patients

  2007cites this paper
• Influence of CYP3A5 Genotype on the Pharmacokinetics and Pharmacodynamics of the Cytochrome P4503A Probes Alfentanil and Midazolam

  2007cites this paper
• The impact of human genetic variation on HIV disease in the era of HAART.

  2006cites this paper